The AM-301 group had greater improvements in Total Nasal Symptom Scores
However, given the hastened timeline and limited data packages, provider uptake may be low, or payers may implement significant restrictions until real-world benefit is demonstrated
Mechanism Wellness Healthy HeartSupplements for heart health and cardiovascular support
Four medications were assessed: semaglutide, tirzepatide, naltrexone/bupropion (Contrave, Currax Pharmaceuticals) and phentermine/topiramate
California Medi-Cal added Wegovy to its list for obesity in late 2024, and Indiana Medicaid expanded coverage in 2025
In the SURMOUNT-1 trial, participants without diabetes achieved average weight loss of 15-20% of baseline body weight over 72 weeks at the highest doses, with somewhat lower reductions observed in people with type 2 diabetes